Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1921 to 1935 of 7689 results

  1. Virtual Wards for Heart Failure

    Awaiting development [GID-MT609] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  2. Virtual Wards for COPD exacerbations

    Awaiting development [GID-MT608] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  3. Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249

    Awaiting development [GID-TA11254] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]

    Awaiting development [GID-TA10897] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]

    In development [GID-TA11368] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Treatments for non-small-cell lung cancer [ID6234]

    In development [GID-TA11289] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

    The topic was stopped after scoping, this means the topic will not proceed to a Technology Appraisal   ...

    Technology appraisal guidance
    Topic selection

  8. Masitinib with riluzole for treating amyotrophic lateral sclerosis ID6257

    In development [GID-TA11071] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Kidney Cancer

    In development [GID-QS10186] Expected publication date: TBC

    Quality standard
    In development

  10. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    In development [GID-TA11086] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development [GID-TA11546] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  12. Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous systemic chemotherapy [ID6414]

    Awaiting development [GID-TA11346] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. myCOPD for managing chronic obstructive pulmonary disease (MTG68)

    Evidence-based recommendations on myCOPD for managing chronic obstructive pulmonary disease.

    Medical technologies guidance
    Published
    31 March 2022
    View recommendations

    Sections for MTG68

  14. Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]

    In development [GID-TA11513] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  15. MT547 QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)

      Status ...

    Medical technologies guidance
    Topic selection